» Articles » PMID: 34771679

Dissecting the Biological Relevance and Clinical Impact of LncRNA MIAT in Multiple Myeloma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Nov 13
PMID 34771679
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The biological impact of long non-coding RNAs (lncRNAs) in multiple myeloma (MM) is becoming an essential aspect of the investigation, which may contribute to understanding the disease's complex pathobiology, providing novel potential therapeutic targets. Herein, we investigated the expression pattern and the clinical relevance of the lncRNA MIAT in MM, taking advantage of the publicly available CoMMpass database. MIAT expression in MM is highly heterogeneous and significantly associated with specific molecular lesions frequently occurring in MM. Transcriptome analyses of MM PCs from patients included in the CoMMpass database indicated a potential involvement of MIAT in different signaling pathways and ribosome biogenesis and assembly. These findings suggest that MIAT deregulation may play a pathogenetic role in MM by affecting both proliferation pathways and, indirectly, the translational process. Although MIAT expression levels seem not to be significantly associated with clinical outcome in multivariate analyses, high MIAT expression levels are associated with bortezomib resistance, this suggesting that MIAT targeting could overcome drug resistance in MM. These findings strongly prompt for further studies investigating the significance of MIAT in MM.

Citing Articles

Long non‑coding RNAs in multiple myeloma (Review).

Yang C, Liang Y, Shu J, Wang S, Hong Y, Chen K Int J Oncol. 2023; 62(6).

PMID: 37144499 PMC: 10198709. DOI: 10.3892/ijo.2023.5517.

References
1.
Fu Y, Liu X, Zhang F, Jiang S, Liu J, Luo Y . Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b. Cell Death Dis. 2019; 10(4):319. PMC: 6456577. DOI: 10.1038/s41419-019-1551-z. View

2.
Barbieri M, Manzoni M, Fabris S, Ciceri G, Todoerti K, Simeon V . Compendium of FAM46C gene mutations in plasma cell dyscrasias. Br J Haematol. 2015; 174(4):642-5. DOI: 10.1111/bjh.13793. View

3.
Todoerti K, Ronchetti D, Favasuli V, Maura F, Morabito F, Bolli N . DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica. 2021; 107(4):921-932. PMC: 8968896. DOI: 10.3324/haematol.2021.278342. View

4.
Taiana E, Ronchetti D, Favasuli V, Todoerti K, Manzoni M, Amodio N . Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica. 2018; 104(2):e72-e76. PMC: 6355474. DOI: 10.3324/haematol.2018.201301. View

5.
Samur M, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A . Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018; 32(12):2626-2635. PMC: 6163089. DOI: 10.1038/s41375-018-0116-y. View